Ocrelizumab Discontinuation vs. Continuation After Safety Events: Comparative Insights from MSBase - PubMed
6 hours ago
- #safety discontinuation
- #multiple sclerosis
- #ocrelizumab
- Ocrelizumab discontinuation due to safety concerns was associated with higher annualized relapse rates compared to continuation.
- No significant difference in time to first relapse was observed between switchers and continuers.
- Trends toward increased risk of confirmed disability worsening at 24 weeks and progression independent of relapse activity were noted in switchers.
- The study highlights the importance of maintaining therapeutic intensity and monitoring during treatment transitions.